MorphoSys Announces Clinical Milestone from Strategic Alliance

Monday, 02. August 2010 07:31
MorphoSys AG /
MorphoSys Announces Clinical Milestone from Strategic Alliance
Processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this announcement.

Third HuCAL Antibody to Enter Clinical Trials in 2010



MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it
will receive a milestone payment from Novartis in connection with the initiation
of a phase 1 clinical trial of a HuCAL-derived, fully human antibody in the
therapeutic area of ophthalmology. Today's news marks the entry of the third
HuCAL-derived antibody into human clinical trials in 2010, following the
advancement of one program each from the alliances with Novartis and Centocor
Ortho Biotech earlier this year.

"This promising new program is our first drug candidate in ophthalmology to
enter the clinic, and underscores the range of indications we cover," commented
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "With three new
clinical starts secured in 2010 we are on track to meet our expectations for the
full year of up to six clinical milestones with various partners. Overall, the
progress of HuCAL drug candidates into human clinical trials is accelerating."

MorphoSys projects that in 2010 between four and six partnered programs could
enter clinical trials. With the recently announced in-licensing of an
Fc-engineered antibody against CD19 from Xencor Inc., MorphoSys now expects up
to 15 proprietary and partnered antibody programs to be in clinical trials by
year-end, at least four of which should be in phase 2.



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys.



This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com










[HUG#1435097]



--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Press Release (PDF):
http://hugin.info/130295/R/1435097/380598.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.

Source: MorphoSys AG via Thomson Reuters ONE
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.